Financing, Pharma

Lyric Pharma grabs $20.4m series A financing

Posted on 02 March 2015

Tags:

Lyric Pharmaceuticals announced the initial closing of a Series A financing round totaling $20.4 million.

The financing, co-led by RiverVest Venture Partners, Sante Ventures and Third Point Ventures, includes participation by Aperture Venture Partners.

Lyric is a clinical-stage pharmaceutical company co-founded in 2013 by David Wurtman, M.D., M.B.A., President & Chief Executive Officer and M. Scott Harris, M.D., Chief Medical Officer.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time

 

The company is developing therapeutics for gastrointestinal indications and in-licensed its initial development candidate in September 2014.

The current financing will enable the company to perform two clinical studies, including a clinical proof of concept study, in addition to other supportive activities.

For further deal information visit Current Agreements (subscription required)

Related

Scorecard: Top partnering deals by value in 2015

View: Top pharmaceutical companies

View: Top biotech companies

Reports: Browse our extensive deal making report portfolio

Print Friendly, PDF & Email

Leave a Reply